Diagnosis and Treatment of Lipodystrophy: a Step-by-step Approach

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2018 Apr 29

PMID 29704234

Citations 75

Authors

D Araujo-Vilar

F Santini

Affiliations

Soon will be listed here.

Abstract

Aim: Lipodystrophy syndromes are rare heterogeneous disorders characterized by deficiency of adipose tissue, usually a decrease in leptin levels and, frequently, severe metabolic abnormalities including diabetes mellitus and dyslipidemia.

Purpose: To describe the clinical presentation of known types of lipodystrophy, and suggest specific steps to recognize, diagnose and treat lipodystrophy in the clinical setting.

Methods: Based on literature and in our own experience, we propose a stepwise approach for diagnosis of the different subtypes of rare lipodystrophy syndromes, describing its more frequent co-morbidities and establishing the therapeutical approach.

Results: Lipodystrophy is classified as genetic or acquired and by the distribution of fat loss, which can be generalized or partial. Genes associated with many congenital forms of lipodystrophy have been identified that may assist in diagnosis. Because of its rarity and heterogeneity, lipodystrophy may frequently be unrecognized or misdiagnosed, which is concerning because it is progressive and its complications are potentially life threatening. A basic diagnostic algorithm is proposed. Effective management of lipodystrophy includes lifestyle changes and aggressive, evidence-based treatment of comorbidities. Leptin replacement therapy (metreleptin) has been found to improve metabolic parameters in many patients with lipodystrophy. Metreleptin is approved in the United States as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy and has been submitted for approval in Europe.

Conclusions: Here, we describe the clinical presentation of known types of lipodystrophy, present an algorithm for differential diagnosis of lipodystrophy, and suggest specific steps to recognize and diagnose lipodystrophy in the clinical setting.

Citing Articles

Pathogenetic therapeutic approaches for endocrine diseases based on antisense oligonucleotides and RNA-interference.

Golounina O, Minniakhmetov I, Salakhov R, Khusainova R, Zakharova E, Bychkov I Front Endocrinol (Lausanne). 2025; 16:1525373.

PMID: 39944202 PMC: 11813780. DOI: 10.3389/fendo.2025.1525373.

Peroxisome proliferator-activated receptor gamma mutation in familial partial lipodystrophy type three: A case report and review of literature.

Wu C, Liu H, Tu L, Hu J World J Diabetes. 2024; 15(12):2360-2369.

PMID: 39676812 PMC: 11580599. DOI: 10.4239/wjd.v15.i12.2360.

Genomic and Bioinformatics Analysis of Familial Partial Lipodystrophy Type 3 Identified in a Patient with Novel PPARγ Mutation and Robust Response to Pioglitazone.

Hummadi A, Yafei S, Mutawwam D, Abutaleb R, Solan Y, Khawaji A Int J Mol Sci. 2024; 25(22).

PMID: 39596129 PMC: 11593357. DOI: 10.3390/ijms252212060.

A Case of Bone Marrow Transplant-Associated Partial Lipodystrophy.

Khan Z, Ali K, Khan A, Teelucksingh S Cureus. 2024; 16(10):e71641.

PMID: 39553096 PMC: 11567169. DOI: 10.7759/cureus.71641.

Acquired Partial Lipodystrophy: Clinical Management in a Pregnant Patient.

Romanisio M, Bighetti L, Daffara T, Mollero E, Pelosini C, Antoniotti V J Endocr Soc. 2024; 8(12):bvae181.

PMID: 39479521 PMC: 11521335. DOI: 10.1210/jendso/bvae181.

References

Huemer C, Kitson H, Malleson P, Sanderson S, Huemer M, Cabral D . Lipodystrophy in patients with juvenile dermatomyositis--evaluation of clinical and metabolic abnormalities. J Rheumatol. 2001; 28(3):610-5. View

Garrapa G, Pantanetti P, Arnaldi G, Mantero F, Faloia E . Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome. J Clin Endocrinol Metab. 2001; 86(11):5301-6. DOI: 10.1210/jcem.86.11.8059. View

Arioglu Oral E, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P . Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002; 346(8):570-8. DOI: 10.1056/NEJMoa012437. View

West R, Lloyd J, Turner W . Familial insulin-resistant diabetes, multiple somatic anomalies, and pineal hyperplasia. Arch Dis Child. 1975; 50(9):703-8. PMC: 1545638. DOI: 10.1136/adc.50.9.703. View

Haque W, Shimomura I, Matsuzawa Y, Garg A . Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. 2002; 87(5):2395. DOI: 10.1210/jcem.87.5.8624. View

Novelli G, Muchir A, Sangiuolo F, Helbling-Leclerc A, DApice M, Massart C . Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet. 2002; 71(2):426-31. PMC: 379176. DOI: 10.1086/341908. View

Van Maldergem L, Magre J, Khallouf T, Gedde-Dahl Jr T, Delepine M, TRYGSTAD O . Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet. 2002; 39(10):722-33. PMC: 1734991. DOI: 10.1136/jmg.39.10.722. View

Misra A, Garg A . Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore). 2003; 82(2):129-46. DOI: 10.1097/00005792-200303000-00007. View

Agarwal A, Simha V, Arioglu Oral E, Moran S, Gorden P, ORahilly S . Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab. 2003; 88(10):4840-7. DOI: 10.1210/jc.2003-030855. View

10.

Simha V, Garg A . Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab. 2003; 88(11):5433-7. DOI: 10.1210/jc.2003-030835. View

11.

Rockall A, Sohaib S, Evans D, Kaltsas G, Isidori A, Monson J . Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. Eur J Endocrinol. 2003; 149(6):561-7. DOI: 10.1530/eje.0.1490561. View

12.

Misra A, Peethambaram A, Garg A . Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore). 2004; 83(1):18-34. DOI: 10.1097/01.md.0000111061.69212.59. View

13.

Garg A . Acquired and inherited lipodystrophies. N Engl J Med. 2004; 350(12):1220-34. DOI: 10.1056/NEJMra025261. View

14.

Csoka A, Cao H, Sammak P, Constantinescu D, Schatten G, Hegele R . Novel lamin A/C gene (LMNA) mutations in atypical progeroid syndromes. J Med Genet. 2004; 41(4):304-8. PMC: 1735741. DOI: 10.1136/jmg.2003.015651. View

15.

Javor E, Ghany M, Cochran E, Arioglu Oral E, DePaoli A, Premkumar A . Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology. 2005; 41(4):753-60. DOI: 10.1002/hep.20672. View

16.

Javor E, Cochran E, Musso C, Young J, DePaoli A, Gorden P . Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes. 2005; 54(7):1994-2002. DOI: 10.2337/diabetes.54.7.1994. View

17.

Garg A, Fleckenstein J, Peshock R, Grundy S . Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. J Clin Endocrinol Metab. 1992; 75(2):358-61. DOI: 10.1210/jcem.75.2.1639935. View

18.

Semple R, Chatterjee V, ORahilly S . PPAR gamma and human metabolic disease. J Clin Invest. 2006; 116(3):581-9. PMC: 1386124. DOI: 10.1172/JCI28003. View

19.

Hennekam R . Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A. 2006; 140(23):2603-24. DOI: 10.1002/ajmg.a.31346. View

20.

Savage D, Semple R, Clatworthy M, Lyons P, Morgan B, Cochran E . Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab. 2008; 94(1):10-6. DOI: 10.1210/jc.2008-1703. View